FDA Brief

Warning letters Drugs

FDA warning letter to

TJA Health, LLC

High riskIssued Jul 17, 2024Posted Sep 17, 2024Division of Pharmaceutical Quality Operations III

FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.

What happened

FDA inspected TJA Health's drug manufacturing facility in Joliet, IL, from January 25 to 29, 2024. The agency found the company failed to test incoming components like glycerin and sorbitol for identity and for dangerous impurities such as diethylene glycol and ethylene glycol, and also failed to monitor its water system for Burkholderia cepacia complex. Additionally, the quality unit did not adequately oversee component approval.

What FDA found

  1. Failed to test each incoming component lot for identity and conformity with specifications, relying instead on supplier certificates.

    21 CFR 211.84(d)(1) and (2)
  2. Failed to test glycerin and sorbitol for diethylene glycol and ethylene glycol using USP limit tests.

    21 CFR 211.84(d)(1) and (2)
  3. Failed to monitor the water system for Burkholderia cepacia complex to ensure suitability for drug manufacturing.

  4. Failed to establish an adequate quality control unit with authority to approve or reject components.

    21 CFR 211.22(a)

What FDA wants

FDA requires a comprehensive review of the material system, a plan to test each component lot for identity and purity, DEG/EG test results within 30 days, a risk assessment for products within expiry, and a quality unit remediation plan. The company must respond in writing within 15 working days.

Who should pay attention

  • brands that buy finished drug products from TJA Health
  • other manufacturers using glycerin or sorbitol in drugs
  • quality managers at oral care product companies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  2. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk